Trial Profile
Xalkori Ros1+Nsclc Drug Use Investigation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Jan 2024 Planned End Date changed from 6 Feb 2026 to 24 Oct 2025.
- 11 Jan 2024 Planned primary completion date changed from 6 Feb 2026 to 24 Oct 2025.
- 20 Sep 2023 Status changed from recruiting to completed.